Mumbai, February 4, 2025 – Metropolis Healthcare Limited (NSE: METROPOLIS, BSE: 542650) released its financial results for the quarter ended December 31, 2024, showing strong year-on-year (YoY) growth in revenue and profitability.
Key Financial Highlights (Standalone)
| Particulars (₹ in Lakhs) | Q3 FY25 | Q2 FY25 | Q3 FY24 | 9M FY25 | 9M FY24 | FY24 (Audited) |
|---|---|---|---|---|---|---|
| Revenue from Operations | 29,688.08 | 32,157.17 | 26,940.87 | 90,459.03 | 81,115.86 | 1,10,342.54 |
| Total Income | 29,991.31 | 32,516.37 | 27,459.72 | 91,404.11 | 82,113.64 | 1,11,542.21 |
| EBITDA (Excl. Other Income) | NA | NA | NA | NA | NA | NA |
| EBITDA Margin (%) | NA | NA | NA | NA | NA | NA |
| Profit Before Tax | 3,679.96 | 5,486.57 | 3,463.13 | 13,338.79 | 11,235.46 | 15,740.91 |
| Net Profit | 2,740.39 | 4,226.20 | 2,669.73 | 10,094.54 | 8,410.95 | 11,588.98 |
| EPS (₹) – Basic | 5.35 | 8.24 | 5.21 | 19.70 | 16.42 | 22.63 |
- Revenue from operations increased 10.2% YoY, driven by higher pathology services demand.
- Net profit grew 2.6% YoY, despite rising costs.
- EPS improved from ₹5.21 to ₹5.35.
Consolidated Financial Highlights
| Particulars (₹ in Lakhs) | Q3 FY25 | Q2 FY25 | Q3 FY24 | 9M FY25 | 9M FY24 | FY24 (Audited) |
|---|---|---|---|---|---|---|
| Revenue from Operations | 32,276.74 | 34,978.88 | 29,111.71 | 98,591.13 | 87,670.88 | 1,20,770.88 |
| Total Income | 32,532.30 | 35,291.78 | 29,342.32 | 99,405.37 | 88,328.64 | 1,21,682.58 |
| Profit Before Tax | 4,233.56 | 6,139.57 | 3,685.49 | 15,480.85 | 12,415.69 | 17,468.89 |
| Net Profit | 3,147.46 | 4,669.77 | 2,728.91 | 11,628.26 | 9,192.96 | 12,845.56 |
| EPS (₹) – Basic | 6.12 | 9.08 | 5.30 | 22.60 | 17.85 | 24.95 |
YoY Growth Analysis (Consolidated)
- Revenue increased 10.9% YoY, reflecting strong performance across subsidiaries.
- Net profit surged 15.3% YoY, supported by improved operational efficiencies.
- EPS increased from ₹5.30 to ₹6.12, demonstrating sustained profitability growth.
Strategic Developments
- Acquisition of Core Diagnostics Private Limited
- On December 9, 2024, Metropolis approved the acquisition of Core Diagnostics Private Limited for ₹24,683 lakhs.
- The acquisition is expected to enhance Metropolis’ advanced diagnostic capabilities.
- The transaction is pending regulatory and closing conditions.
- Employee Stock Incentives
- The Nomination and Remuneration Committee granted:
- 65,700 RSUs in May 2024
- 58,000 RSUs in June 2024
- 22,500 RSUs in November 2024
- These are part of the Metropolis Restricted Stock Unit Plan – 2020.
- The Nomination and Remuneration Committee granted:
Management Commentary
Ameera Shah, Chairperson and Whole-time Director, stated:Market Outlook & Future Growth
- Expansion Plans: The Core Diagnostics acquisition is expected to expand Metropolis' footprint in specialized diagnostics.
- Pathology Demand Growth: Increasing awareness of preventive healthcare is driving demand for diagnostic services.
- Operational Efficiency Initiatives: The company is focused on improving cost efficiencies to maintain margins despite inflationary pressures.